Article

Regeneron, Bayer launch trial of aflibercept for CNV

Regeneron and Bayer HealthCare have begun a Phase III clinical trial in collaboration with the Singapore Eye Research Institute (SERI) to investigate the efficacy and safety of aflibercept ophthalmic solution (VEGF Trap-Eye) in patients with choroidal neovascularization (CNV) of the retina as a result of pathologic myopia.

Tarrytown, NY, Berlin, and Singapore-Regeneron and Bayer HealthCare have begun a phase III clinical trial in collaboration with the Singapore Eye Research Institute (SERI) to investigate the efficacy and safety of aflibercept ophthalmic solution (VEGF Trap-Eye) in patients with choroidal neovascularization (CNV) as a result of pathologic myopia. The trial has started in Japan and other Asian countries, including China, Korea, Singapore, and Taiwan.

Aflibercept previously has met its primary efficacy endpoint in a phase III trial for neovascular age-related macular degeneration.

SERI has been appointed as the Asian reading center partner for this study. The Singapore Advanced Imaging Laboratory for Ocular Research (SAILOR) will serve as the first reading center for the aflibercept studies in the region.

“Myopia is a common problem in Singapore and Asia. In particular, myopic CNV, which affects certain groups of people with higher degrees of myopia, may lead to vision loss,” said Wong Tien Yin, MBBS, PhD, MMed, MPH, FRCS, FRANZCO, director of SERI and co-director of SAILOR. “There remains uncertainty regarding the best methods of treatment for myopic CNV, and this new trial will go toward addressing this clinical need.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.